A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
This study examined the potential of L-Deprenyl, a selective monoamine oxidase-B (MAO-B) inhibitor, for the treatment of neuroleptic-induced parkinsonism (NIP). Thirty-one consecutive schizophrenic or schizophreniform patients were treated with haloperidol in a flexible dose design. Nineteen of them developed NIP and were administered adjunctive L-Deprenyl 10 mg/d for six weeks in an open fixed-dose design. One patient had to be withdrawn from the study because of exacerbation of the NIP. Severity of NIP was mild to moderate throughout the whole study period in all other cases. Five patients were considered to require biperiden 2-4 mg/d in addition to L-Deprenyl after two weeks of treatment, although they did not differ from the other 13 patients in any of the variables studied. A significant improvement in NIP was found in both groups of patients, with no psychotic exacerbation or a change in the dosage of haloperidol. These findings suggest that selective MAO-B inhibitors may be effective in some patients with mild to moderate NIP.
Rapoport
A
A
Department of Neurology, E. Wolfson Medical Center, Holon, Israel.
Stein
D
D
Schwartz
M
M
Levin
J
J
Stier
S
S
Elizur
A
A
Rabey
J M
JM
D000328:Adult; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data*; D012044:Regression Analysis; D012559:Schizophrenia / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline